Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2015-11-03 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
独立董事关于聘任公司财务负责人、财务总监的独立意见
Regulatory Filings Classification · 95% confidence The document is a statement from independent directors regarding the appointment of the company's financial officer and financial director. It contains opinions on the qualifications and appointment procedures but does not include financial data, report content, or regulatory filings. It is not an annual report, audit report, or management report. It is also not a board or management change announcement in the typical sense of announcing new board members or senior management changes but rather an independent opinion on a specific appointment. Given the nature and length (435 characters), it is best classified as a Regulatory Filing (RNS), which covers miscellaneous filings that do not fit other categories.
2015-11-03 Chinese
关于使用部分暂时闲置募集资金进行现金管理的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the use of temporarily idle raised funds for cash management. It details the approval by the board and supervisory committee, the amount of funds involved, the types of investment products, risk control measures, and opinions from independent directors and the sponsor institution. The document references regulatory guidelines and approvals but does not contain actual financial statements or comprehensive financial data. It is a formal announcement about the company's plan to use idle raised funds for cash management, not a full financial report or audit. The document length is 3179 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this fits best under the category of a Regulatory Filing (RNS), as it is a regulatory announcement about fund usage and compliance with relevant rules, not an Annual Report, Interim Report, or Capital/Financing Update per se.
2015-11-03 Chinese
八届一次监事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the first meeting of the eighth supervisory board of Kunming Pharmaceutical Group Co., Ltd. It includes election of the supervisory board chairman and approvals related to non-public share issuance and use of funds. The document is short (1042 characters) and primarily reports on board decisions and meeting outcomes. It does not contain financial statements, detailed financial data, or full reports. It is not an annual or interim report, nor an earnings release. It is not a proxy solicitation or voting results announcement, but a board/management information announcement about supervisory board decisions. Therefore, the best fitting category is Board/Management Information (MANG).
2015-11-03 Chinese
关于修订公司章程的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding amendments to the company's articles of association. It details the approval and completion of a non-public issuance of shares, changes in registered capital, and updates to the company's share capital structure. The document references regulatory approvals and board resolutions but does not contain full financial statements or detailed financial performance data. It is primarily an announcement about capital changes and corporate governance updates related to share issuance and amendments to the company charter. Given the content and length (1670 characters), it fits best as a Capital/Financing Update (CAP) rather than a full report or regulatory filing.
2015-11-03 Chinese
关于利用闲置自有资金进行保本投资理财业务的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the use of idle self-owned funds for principal-guaranteed investment and wealth management business. It details the board and supervisory committee approvals, investment scope, risk analysis, and independent directors' and supervisors' opinions. The document is an announcement of a corporate decision and investment plan, not a financial report, earnings release, or regulatory filing. It does not contain financial statements or detailed financial data. It is also not a notice of voting results or a proxy solicitation. Given the content and length (2186 characters), it fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about corporate investment activities that does not fit other specific categories.
2015-11-03 Chinese
中审亚太会计师事务所（特殊普通合伙）关于公司以自筹资金预先投入募投项目的鉴证报告
Audit Report / Information Classification · 95% confidence The document is a verification report issued by a certified public accounting firm regarding the use of self-raised funds pre-invested into fundraising projects by Kunming Pharmaceutical Group Co., Ltd. It references regulatory approvals from the China Securities Regulatory Commission and the Shanghai Stock Exchange, details the amount of funds raised through a non-public stock issuance, and explains the investment projects and the use of self-raised funds to cover shortfalls. The document includes an auditor's attestation and verification opinion on the special statement about the pre-investment of self-raised funds into fundraising projects. This is a standalone audit-related verification report, not a full annual or interim report, nor an announcement or presentation. It fits the category of an Audit Report / Information (AR) as it contains an auditor's verification opinion on a specific financial matter related to fundraising and investment projects. FY 2015
2015-11-03 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.